Results 41 to 50 of about 1,361 (136)

8526 The WEE1 Kinase Inhibitor Adavosertib - A Promising Therapeutic Enhancer Of Cytotoxic Therapies In Advanced Adrenocortical Carcinoma [PDF]

J Endocr Soc
Background: Adrenocortical cancer (ACC) is a rare malignant tumor associated with poor prognosis and limited therapeutic options in advanced cases. Inhibition of WEE1 with adavosertib has emerged as novel strategy for cancer therapy.
Schauer, M P, Steinhauer, S, Sigala, S, Fassnacht, M, Ronchi, C L; id_orcid, Tamburello, M, Weber, J, Wierman, M E, Kiseljak-Vassiliades, K, Holmstoen, T, Landwehr, L S, Urlaub, H, Hudecek, M, Hantel, C, Altieri, B, Kircher, S, Sbiera, S, Kimpel, O, Lippert, J, Detomas, M   +19 more
europepmc   +2 more sources

Loss of SETD2 in wild‐type VHL clear cell renal cell carcinoma sensitizes cells to STF‐62247 and leads to DNA damage, cell cycle arrest, and cell death characteristic of pyroptosis

Molecular Oncology, Volume 19, Issue 4, Page 1244-1264, April 2025.
Vulnerability to the small molecule STF‐62247 is observed in SETD2‐inactivated VHL‐positive clear cell renal cell carcinoma (ccRCC) cells. DNA damage and loss of CDC25A leads to cell cycle arrest in S phase. Cleavage of caspase‐3 (CASP3) and gasdermin E (GSDME) suggests cell death by pyroptosis.
Mathieu Johnson, Sandra Turcotte
wiley   +1 more source

Therapeutic potential of targeting the FLNA‐regulated Wee1 kinase in adrenocortical carcinomas

International Journal of Cancer, Volume 156, Issue 6, Page 1256-1271, 15 March 2025.
What's new? Adrenocortical carcinoma (ACC) is a rare but aggressive cancer of the adrenal gland. In many ACC cases, expression of the cytoskeletal protein filamin A (FLNA) is dramatically reduced; its presence in a tumour is associated with less aggressiveness.
Emanuela Esposito, Giusy Marra, Rosa Catalano, Sara Maioli, Emma Nozza, Anna Maria Barbieri, Constanze Hantel, Guido Di Dalmazi, Sandra Sigala, Jens Geginat, Elisa Cassinotti, Ludovica Baldari, Serena Palmieri, Alessandra Mangone, Alfredo Berruti, Emanuele Ferrante, Giovanna Mantovani, Erika Peverelli   +17 more
wiley   +1 more source

Supplementary Data from Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition

, 2019
suppl figures 1-6. SF1: Myt1 knockdown sensitizes breast cells to Adavosertib; SF2: Wee1 knockdown mimics Adavosertib treatment; SF3: Adavosertib does not inhibit Myt1 activity; SF4: Adavosertib resistant cells do not prematurely enter mitosis; SF5 ...
Won-Shik Choi (14936028), Cody W. Lewis (14936022), Armin M. Gamper (14936040), Ellen Homola (14936034), Amirali B. Bukhari (103477), Joanne D. Smith (14936031), Shelagh D. Campbell (14936037), Edric J. Xiao (14936025), John R. Mackey (102521), Gordon K. Chan (14936043)   +9 more
core   +1 more source

DataSheet_1_Treatment options for recurrent platinum-resistant ovarian cancer: A systematic review and Bayesian network meta-analysis based on RCTs.docx

, 2023
BackgroundThere are a variety of treatment options for recurrent platinum-resistant ovarian cancer, and the optimal specific treatment still remains to be determined. Therefore, this Bayesian network meta-analysis was conducted to investigate the optimal
Shengpeng Liu (2157241), Chen Yin (4182043), Haowen Yan (8336439), Guorong Zou (4603747), Wei Wang (17594), Juan Li (146180)   +5 more
core   +1 more source

Supplementary Figure S5 from Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck

, 2019
Supplementary Figure S5 related to Figure 5H. (A) Heat map QIF of pCDK1 expression intensity in FaDu xenograft mice treated with (a) vehicle, (b) alisertib, (c) adavosertib or (d) alisertib+adavosertib. Scores range from very low (purple) to high (yellow)
Jeffrey P. Townsend (14963915), Dong-hua Yang (15012759), Ja Seok Koo (14888484), Kyung Jin Eoh (8568471), Wendell G. Yarbrough (232305), Janaki Parameswaran (15012753), Erica A. Golemis (14949004), Natalia Issaeva (839371), Stephen G. Gaffney (15012762), Ilya G. Serebriiskii (14893961), Barbara Burtness (550227), Jong Woo Lee (360063), Fang Zhu (185566), Ranee Mehra (5707862), Teresa Sandoval-Schaefer (15012756), Roshan Sharma (5904719), Elizabeth B. Perry (14920176)   +16 more
core   +1 more source

Efficacy and Safety of Adavosertib in Platinum-Resistant and RecurrentOvarian Cancer: A Systematic Review and A Meta-Analysis

Journal of Gynecology Research Reviews & Reports
Introduction: Ovarian cancer is a leading cause of mortality among gynaecological malignancies. According to estimates from the American Cancer Society for 2024, approximately 19,680 women in the United States will be newly diagnosed with ovarian cancer, and about 12,740 women will succumb to the disease.
Pavan Kumar Reddy Kalluru, Sai Sudha Valisekka, Deekshitha Kuchi, Abijay Reddy Bhoomireddy, Apoorva Cherukuri, Gaurav Venkat Cuddapah, Sai Goutham Reddy Yartha, Sowmya Manjari Siddenthi, Niravkumar Brahmbhatt, Pawan Kumar Thada, Samhitha Gundakaram, Haritha Reddy Kalluru   +11 more
openaire   +1 more source

Adavosertib-encapsulated metal-organic frameworks for p53-mutated gallbladder cancer treatment via synthetic lethality

Science Bulletin
Adavosertib (ADA) is a WEE1 inhibitor that exhibits a synthetic lethal effect on p53-mutated gallbladder cancer (GBC). However, drug resistance due to DNA damage response compensation pathways and high toxicity limits further applications. Herein, estrone-targeted ADA-encapsulated metal-organic frameworks (ADA@MOF-EPL) for GBC synthetic lethal ...
Shijie, Li, Sarun, Juengpanich, Win, Topatana, Tianao, Xie, Lidan, Hou, Yiyuan, Zhu, Jiadong, Chen, Yukai, Shan, Yina, Han, Ziyi, Lu, Tianen, Chen, Charlie, Topatana, Bin, Zhang, Jiasheng, Cao, Jiahao, Hu, Jiafei, Yan, Yingxin, Chen, Zhen, Gu, Jicheng, Yu, Xiujun, Cai, Mingyu, Chen   +20 more
openaire   +2 more sources

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer

, 2020
Triple-negative breast cancer (TNBC) is an aggressive subtype defined by lack of hormone receptor expression and non-amplified HER2. Adavosertib (AZD1775) is a potent, small-molecule, ATP-competitive inhibitor of the Wee1 kinase that potentiates the ...
Sarah J. Hartman, D. Ryan Ormond, Todd M. Pitts, Diana Cittelly, Stacey M. Bagby, Brian Gittleman, John J. Tentler, Wells A. Messersmith, Dennis M. Simmons, Betelehem W. Yacob, Jennifer R. Diamond, S. Gail Eckhardt   +11 more
core   +1 more source

Supplementary Table S4 from Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial

Summary of WEE1 inhibitor adavosertib clinical ...
Samuel Abbou (15119500), Susanne A. Gatz (17977394), Souad Nebchi (17977412), Xavier Paoletti (17977427), Marc Deloger (15061677), Lynley V. Marshall (15110912), Peter G.S. Mortimer (15112775), Gilles Vassal (17977436), Caroline Brard (15036380), Kowser Miah (17977433), Birgit Geoerger (14952291), Daniel Hübschmann (17977409), Robert Godin (17977430), Jonathan Rubino (17977400), Estelle Thebaud (17977418), Nicolas André (15119506), Isabelle Aerts (17977415), Francisco Bautista (17314452), Marc Rübsam (17977406), Emilie De Carli (17977421), Anne C. Harttrampf (17977397), Windy Rondof (17977403), Anne Sophie Defachelles (17977424)   +22 more
core   +1 more source